BÜHLMANN Laboratories AG of Schönenbuch at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

BÜHLMANN Laboratories AG

Baselstr. 55, 4124 Schönenbuch
Switzerland
Telephone +41 61 4871212
Fax +41 61 4871234
info@buhlmannlabs.ch

Hall map

MEDICA 2019 hall map (Hall 3): stand F63

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

  • 03  Diagnostic Tests
  • 03.07  Other diagnostics

Other diagnostics

Our products

Product category: Immuno assay testing

MRP8/14

MRP8/14 is an early and sensitive inflammation marker. It is released immediately in response to local inflammation. In contrast, other inflammatory markers are generated by downstream pathways and require de novo synthesis. Therefore, MRP8/14 is an ideal target for monitoring disease activity of Rheumatoid Arthritis. Our assays for MRP8/14 allow for precise and sensitive measurement of this important marker.

More Less

Product category: Immuno assay testing

Circulating Immunecomplexes (CIC)

Circulating Immunecomplexes (CIC) are detectable in a variety of systemic disorders. They provide useful, clinical information regarding immunopathology, prognosis and follow-up of rheumatic and autoimmune disorders. Bühlmann Labs offers a well-established and widely used assay that provides sensitive results within 2 hours.

More Less

Product category: Immuno assay testing

Anti C1q antibodies

Measurement of anti-C1q autoantibodies in patients with Systemic Lupus Erythematosus (SLE) allows to determine the risk of developing an active lupus nephritis. Our anti-C1q autoantibody ELISA can be used as a simple way to exclude the risk of renal flair in the following months. In the case of active lupus nephritis, consecutive determination of anti-C1q antibodies is a tool to evaluate the efficacy of immunosuppressive treatment.

More Less